Using our FateControl™ technology, we create antibody-drug conjugates (ADCs) that are more effectively internalized by their target tissue, thereby ensuring that a larger fraction of every dose is ultimately delivered to its intended destination.
Unlocking the Full Potential of ADCs for Patients
After more than 40 years of development, antibody-drug conjugates (ADCs) have emerged as a powerful treatment option in precision oncology. However, outside of a subset of optimal molecular targets, ADC performance continues to be limited by toxicity, leaving the vast majority of cancer patients unable to benefit from this otherwise promising therapeutic approach.
At Mythic Therapeutics, we solve this problem by focusing on how the ADC and its target are trafficked through cells.
Using our FateControl™ technology, we manipulate the trafficking of the ADC in cells to increase uptake in the desired tissue while avoiding payload release in other, undesired tissues. This approach simultaneously increases therapeutic potency and improves the drug’s tolerability, thereby enabling our medicines to treat broader patient population than previously possible.
We are using our platform to build a pipeline of innovative and impactful ADCs.